Best Life Sciences Tech Companies in Cambridge, United Kingdom
The 32 best Life Sciences Tech companies in Cambridge, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Healx.
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Tech companies in Cambridge
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Healx Provider of AI-powered drug discovery solutions for rare diseases 64Innovation top 25%AI top 26%Moat top 26%Patents top 27% All 12 signals ▾Innovationtop 25% AItop 26% Moattop 26% Patentstop 27% Fundingtop 29% Talenttop 38% Growthtop 42% Techtop 48% Globalbottom 47% Marketbottom 46% Fin. healthbottom 28% Newsbottom 18% Innovation: 105 patents (top 10% of patent-holders) · 57 filings since 2022 vs 48 in 2017-21 AI: Classified as an AI company · Product described with: ai-powered, machine learning rank vs industry peers · Fliar Intelligence Index 64/100 | $115M | 27 mo ago | Series C | 80 80 → 69 (-14%) | David Brown Co-Founder | WordPressMySQLPHP+22 | 105 patents Drug repurposing of existing compounds for rare cancers and polycystic kidney disease | — |
| 2 | Eagle Genomics Developer of cloud-based software solutions for genomic analysis | $39M | 37 mo ago | Series C | 125 | Anthony Finbow CEO | HubSpot CMS HubApple iCloud MailMicrosoft 365+17 | — | — |
| 3 | De Novo Pharmaceuticals Provider of computational drug design software and services | $24M | 303 mo ago | Deadpooled | 11 | Philip Dean Co-Founder | — | 6 patents Novel antibacterial enzyme inhibitor compounds targeting bacterial resistance mechanisms | — |
| 4 | Eleven AI-based RNA drug development platform for researchers 55Growth top 28%Talent top 28%Funding top 31%AI top 45% All 8 signals ▾Growthtop 28% Talenttop 28% Fundingtop 31% AItop 45% Newsbottom 48% Techbottom 44% Globalbottom 37% Marketbottom 25% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 55/100 | $22M | 18 mo ago | Seed | 12 12 → 28 (+133%) | Shaul Ilan Co-Founder | WordPressMySQLPHP+17 | — | — |
| 5 | 14M Genomics Provider of a technology that utilizes next gen sequencing and proprietary analytics for cancer diagnostics | $20M | 142 mo ago | Deadpooled | 20 | — | — | — | — |
| 6 | Broken String Biosciences Developer of biopharmaceutical products & cell therapies by using genome sequencing data | $15M | 37 mo ago | Series A | 4 | Felix Dobbs Co-Founder & CEO | WordPress Site EditorWordPressMySQL+24 | 9 patents High-throughput nucleic acid sequencing and double-strand break detection methods. | — |
| 7 | Qureight AI enabled data curation platform for drug development | $11M | 30 mo ago | Series A | 7 | — | Apple iCloud MailMicrosoft 365Three.js+23 | 7 patents AI-driven quantitative analysis of lung fibrosis using medical imaging software | — |
| 8 | CardiaTec Provider of novel therapeutic discovery platform for cardiovascular diseases | $11M | 25 mo ago | Seed | 5 | Thelma Zablocki Co-Founder & COO | — | — | — |
| 9 | Omnigen Biodata Moon - Experienced digital folks who craft interactive products and experiences | $9M | 21 mo ago | Series A | 15 | Manjinder Sandhu Founder & CEO | — | — | — |
| 10 | Repositive Developer of software platform to facilitate data access, data sharing, and data collaborations | $4M | 116 mo ago | Series A | 9 | — | WordPress Site EditorWordPressMySQL+13 | — | — |
| 11 | Intellegens Provider of deep learning platform for applications in multiple industries | $2M | 38 mo ago | Funding Raised | 23 23 → 18 (-22%) | Ben Pellegrini Chief Executive Officer | WordPressApple iCloud MailGoogle Workspace+35 | — | — |
| 12 | Optibrium Provider of an AI based software solutions for small molecule design, optimization and data analysis | $1M | 52 mo ago | Seed | 62 62 → 49 (-21%) | — | WordPressApple iCloud MailMicrosoft 365+26 | 9 patents Computational drug discovery platforms for compound selection and multi-parameter sensitivity analysis | — |
| 13 | Tailor Bio Developer of targeted therapies for cancers with chromosomal instability | $772K | 51 mo ago | Funding Raised | 10 | Geoff Macintyre Founder | — | — | — |
| 14 | Cresset Provider of software solutions for computational chemistry | $298K | 49 mo ago | Seed | 46 46 → 88 (+91%) | — | WordPressApple iCloud MailMicrosoft 365+29 | — | — |
| 15 | Genestack Bioinformatics platform for genomics research and development | $138K | 132 mo ago | Funding Raised | 9 | — | — | — | — |
Top 12 Life Sciences Tech companies in Cambridge
#1
Seed · Cambridge, England · founded 2020 · 12 employees$22Mraised▾
AI-based RNA drug development platform for researchers. The company harnesses the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process against influenza and SARS-CoV-2.
- Apr 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$320K
- Aug 2022Seed$18M
- Aug 2022Grant (prize money)$4M
#2
Series A · Cambridge, England · founded 2019 · 15 employees$9.5Mraised▾
We design across paper, web, tablet, mobile, gaming, TV or book - wherever the ideas go.
- Jan 2025Series A$1.6M
- Sep 2024Series A$4.5M
- Sep 2023Seed$623.1K
- May 2022Seed$2.2M
#3
Series C · Cambridge, England · founded 2014 · 80 employees$115.4Mraised▾
Provider of AI-powered drug discovery solutions for rare diseases. It helps identify new drug candidates, repurpose existing compounds, and accelerate rare disease research and development. The company combines machine learning, biomedical knowledge graphs, and expert drug discovery workflows to improve the speed and success rate of bringing treatments to patients.
- Aug 2024Series C$47M
- 2022Series C—
- Oct 2019Series B$56M
- Jul 2018Series A$10M
#4
Seed · Cambridge, England · founded 2021 · 5 employees$10.9Mraised▾
Provider of novel therapeutic discovery platform for cardiovascular diseases. The company leverages human multiomics data to navigate complex disease biology to identify novel and differentiated therapeutics for cardiovascular diseases.
- Sep 2024Seed$6.5M
- Mar 2023Seed$2.7M
- Jun 2022Seed$1.7M
#5
Series C · Cambridge, England · founded 2008 · 125 employees$38.7Mraised▾
Eagle Genomics provides cloud-based software solutions for genomic analysis. The company's products include Eaglecore and EagleEnsembl. Eaglecore is a platform for collaborative information management in R&D. EagleEnsembl is a platform for searching and analyzing genomic data.
- Sep 2023Series C$3.7M
- Oct 2022Series C$20M
- Oct 2020Series B$9M
- Jan 2019Series A$3.5M
#6
Series A · Cambridge, England · founded 2018 · 7 employees$11.2Mraised▾
AI enabled data curation platform for drug development. It specializing in AI-powered data and imaging curation to advance understanding of lung and heart diseases, accelerating drug development through clinical trials, new endpoints, and synthetic control arms.
- Apr 2024Series A$8.5M
- Feb 2022Seed$2M
- Sep 2021Seed$684.4K
#7
Series A · Cambridge, England · founded 2020 · 4 employees$15Mraised▾
Developer of biopharmaceutical products & cell therapies by using genome sequencing data. It has developed sequencing tools that help in the development of medicines, including cell and gene therapies for the treatment of cancer, immunological health & other diseases. It develops INDUCE-seq technology for measuring DNA breaks throughout the genome & also determines the mechanism of DSB repair that facilitates the development of therapeutic genome editing.
- Sep 2023Series A$15M
- Jan 2022Seed—
- Feb 2021Seed—
#8
Funding Raised · Cambridge, England · founded 2017 · 23 employees$2Mraised▾
Provider of a deep learning platform for applications in multiple industries. It provides a platform to extract data and optimize formulations, products & procedures. Some industrial applications include materials development, additive manufacturing, drug discovery, chemistry, etc. Industries can use the platform to train datasets and create deep learning algorithms for usage in data science in multiple industries
- Sep 2023Grant (prize money)$2M
- Jul 2020Grant (prize money)—
- Feb 2019Grant (prize money)—
- Sep 2018Grant (prize money)—
#9
Deadpooled · Cambridge, England · founded 1999 · 11 employees$23.9Mraised▾
Provider of computational drug design software and services. The company focused on the development of biomarker-driven precision medicines. It develops drugs in therapeutic areas such as oncology, neurology, metabolic, cardiology, and immunology.
- Jul 2001Series B$23.9M
- 2000Series A—
#10
Deadpooled · Cambridge, England · founded 2014 · 20 employees$19.7Mraised▾
Provider of a technology that utilizes next gen sequencing and proprietary analytics for cancer diagnostics. The company employs two proprietary algorithms to analyze and report associations between tumor genomics and patient prognosis. GABRIEL analyzes patient samples for cancer genomic data and generates personalized profiles of somatic mutations, and RAPHAEL is a web-based reporting portal that can be accessed by healthcare providers.
- Dec 2014Series A$19.7M
#11
Series A · Cambridge, England · founded 2015 · 9 employees$4.1Mraised▾
Repositive is developing a platform for efficient and ethical data sharing for genomics research in cancer and rare diseases. It enables genomic data discovery, simplifies metadata organization and provides secure data sharing and collaborations through a privacy-preserving platform. Its mission is to maximize the benefit derived from genomic data within the limit of the donor's consent for data access and use.
- Feb 2017Series A$3.3M
- Mar 2016Grant (prize money)—
- Jan 2016Seed$711.9K
- Dec 2015Seed$912.7K
#12
Seed · Cambridge, England · founded 2009 · 62 employees$1.3Mraised▾
Optibrium provides AI-based software solutions for small molecule design, optimization, and data analysis. Products include StarDrop- a suite of software for guiding decisions in drug discovery, Cerella which is AI-enabled used for drug discovery techniques, Augmented Chemistry which has been built for experimental data analysis and Ocura which allows users to view molecules with summaries, structures, and more.
- Jun 2022Seed—
- Feb 2021Seed—
- Sep 2018Grant (prize money)$1.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Cambridge is moving
A read on the academic research around Biotechnology in Cambridge — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 62 papers.
- University of Cambridge54
- Cambridge School4
- Cambridge University Hospitals NHS Foundation Trust4
- Cancer Research UK Cambridge Center3
- Cambridge Life Sciences1
- Chromatin1→3
- Antibody3
- Gene2
- Transcription (linguistics)2
- Probiotic2
- Bacteria2
- Cell adhesion1
- Cell adhesion molecule1
- Follicular dendritic cells1
- Endocytosis1
- Neural cell adhesion molecule1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.